Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Mammadzadeh, Aytaj [1 ]
Peng, Fulei [2 ]
Atrash, Shebli [3 ,4 ]
Hashmi, Hamza [3 ,5 ]
Mohan, Meera [3 ,6 ]
Alkharabsheh, Omar [3 ,7 ]
Afrough, Aimaz [3 ,8 ]
Cui, Wei [3 ,9 ]
Mahmoudjafari, Zahra [3 ,10 ]
Abdallah, Al-Ola [11 ,12 ]
机构：
[1] Azerbaijan Med Univ, Dept Internal Med, Baku, Azerbaijan
[2] Mercy St Louis Hosp, Dept Internal Med, St Louis, MO USA
[3] US Myeloma Res Innovat Res Collaborat USMIRC, Westwood, KS USA
[4] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[5] Med Univ South Carolina, Dept Hematol Med Oncol, Charleston, SC 29425 USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Univ S Alabama, Mitchell Canc Inst, Div Hematol Oncol, Mobile, AL USA
[8] UT Southwestern Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Internal Med, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[9] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[10] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA
[11] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA
[12] US Myeloma Innovat Res Collaborat USMIRC, Westwood, KS USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4277 / 4278
页数：2
相关论文
共 50 条
  • [1] Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT)
    Venkatesh, Priyanka
    Atrash, Shebli
    Paul, Barry
    Alkharabsheh, Omar
    Afrough, Aimaz
    Mahmoudjafari, Zahra
    Mushtaq, Muhammad Umair
    Hashmi, Hamza
    Davis, James A.
    Abdallah, Al-Ola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Pooled Analysis of MagnetisMM Studies: Efficacy and Safety of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Previously Exposed to B-cell Maturation Antigen (BCMA)-Directed Therapies
    Ajay, Nooka K.
    Alexander, Lesokhin M.
    Mahamad, Mohty
    Ruben, Niesvizky
    Christopher, Maisel
    Bertrand, Arnulf
    Sarah, Larson M.
    Nina, Asya Varshavsky-Yanovsky
    Xavier, Leleu
    Lionel, Karlin
    David, Vesole H.
    Nizar, Bahlis J.
    de Larrea Carlos, Fernandez
    Noopur, Raje
    Eric, Leip
    Umbarto, Conte
    Mohamed, Elmeliegy
    Andrea, Viqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S27 - S28
  • [3] Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma
    Hoeynck, Brian
    Hwang, Wei-Ting
    Garfall, Alfred L.
    Susanibar-Adaniya, Sandra Patricia
    Vogl, Dan T.
    Waxman, Adam
    Stadtmauer, Edward A.
    Cohen, Adam D.
    BLOOD, 2022, 140 : 10081 - 10083
  • [4] B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma
    Abramson, Hanley N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 24
  • [5] Preferences among patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) in the era of B-cell maturation antigen (BCMA)-directed T-cell-engaging therapies
    Ailawadhi, Sikander
    Inocencio, Timothy J.
    Mansfield, Carol
    Chintakayala, Phani
    Bussberg, Cooper
    Chi, Lei
    Harnett, James
    Kroog, Glenn Scott
    Houvras, Yariv
    Rodriguez-Lorenc, Karen
    Ma, Qiufei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Preferences Among Patients With Triple-Class Exposed (TCE) Relapsed/ Refractory Multiple Myeloma (RRMM) in the Era of B-Cell Maturation Antigen (BCMA)-Directed T-Cell-Engaging Therapies
    Ailawadhi, Sikander
    Inocencio, Timothy J.
    Mansfield, Carol
    Chintakayala, Phani
    Bussberg, Cooper
    Chi, Lei
    Harnett, James
    Kroog, Glenn
    Houvras, Yariv
    Rodriguez-Lorenc, Karen
    Ma, Qiufei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S554 - S554
  • [7] Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naive in Relapsed/Refractory Multiple Myeloma
    Snyder, Jordan
    Graf, Kevin
    Davis, James A.
    Mckenna, Marshall
    Tiger, Yun Kyoung
    Laharwal, Mehak M.
    Mewawalla, Prerna
    Alkharabsheh, Omar
    Hashmi, Hamza
    Shaikh, Hira
    Lochner, Jonathan
    Chang, Darryl
    Atrash, Shebli
    Habib, Alma
    Venkatesh, Priyanka
    Mahmoudjafari, Zahra
    Ahmed, Nausheen
    Mushtaq, Muhammad Umair
    Abdallah, Al-Ola
    Green, Kimberly M.
    Khan, Abdullah Mohammad
    BLOOD, 2024, 144 : 24117 - 24118
  • [8] Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah M.
    Varshavsky-Yanovsky, Asya Nina
    Leleu, Xavier
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    Fernandez de Larrea, Carlos
    Raje, Noopur
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S496 - S497
  • [9] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah Marie
    Yanovsky, Asya Varshavsky
    Leleu, Xavier P.
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    de Larrea, Carlos Fernandez
    Raje, Noopur S.
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    Manier, Salomon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Efficacy and safety of elranatamab in pts with relapsed/ refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies
    Raab, M. S.
    Hanel, M.
    Nooka, A. K.
    Lesokhin, A. M.
    Mohty, M.
    Niesvizky, R.
    Maisel, C.
    Arnulf, B.
    Larson, S. M.
    Varshavsky-Yanovsky, A. N.
    Leleu, X.
    Karlin, L.
    Vesole, D. H.
    Bahlis, N. J.
    de larrea, Fernandez C.
    Raje, N.
    Leip, E.
    Conte, U.
    Elmeliegy, M.
    Viqueira, A.
    Manier, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 232 - 232
12345